Skip to content
lifestyle.fictiontalk.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nanobiotix S.A.
Voting Rights and Shares Capital of the Company
July 30, 2026
NANOBIOTIX Announces Closing of Global Offering
May 26, 2026
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
May 22, 2026
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
May 21, 2026
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
May 21, 2026
Nanobiotix Announces Launch of Global Follow-On Offering
May 20, 2026
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
May 17, 2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
May 4, 2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
April 20, 2026
Voting Rights and Shares Capital of the Company
April 7, 2026
1
2
Next Page
→